Indeed, when AD is in the clinical stage, Aβ and tau accumulations have already induced extensive neuronal damage in multiple areas of the brain and could be too late for the possible FNDC5 role as of any other compound in AD treatment [82]. Here, MAPT is linked to Alzheimer disease.